Lupin Limited — Investor Meet, 17-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Lupin reported a strong Q3 FY26, with revenues hitting a new high of INR 7,168 Cr (+24% YoY) and EBITDA margins reaching 31.1%. US sales surged to USD 350 million (+46% YoY), boosted by new launches like Tolvaptan and Pegfilgrastim approval. India's core prescription business grew 10.9%. Management highlighted broad-based growth, pipeline for biosimilars, injectables, and specialty products (including Semaglutide in India). They anticipate FY26 EBITDA margins of 27-28% (upgraded outlook) and FY27 margins around 24-25%. Focus remains on innovation, complex products, and strategic acquisitions for future growth. The tone is confident about sustainable long-term performance.